Thorinane Euroopa Liit - eesti - EMA (European Medicines Agency)

thorinane

pharmathen s.a. - naatrium enoksapariin - venoosne trombemboolia - antitrombootilised ained - thorinane on näidustatud täiskasvanute jaoks: - profülaktika venoosne trombemboolia, eriti patsientidel, toimumas ortopeedilised, üld-või onkoloogilised kirurgia. - profülaktika venoosne trombemboolia patsientidel bedridden tõttu ägedad haigused sh äge südamepuudulikkus, äge hingamispuudulikkus, ägedad infektsioonid, samuti reumaatiliste haiguste ägenemist põhjustab peatamine patsiendi kohta (kehtib tugevused 40 mg/0. 4 ml). - ravi süvaveenide tromboos (dvt), keeruline või lihtne, mida kopsuemboolia. - ravi ebastabiilse stenokardia ja mitte q-laine, müokardi infarkt, koos atsetüülsalitsüülhape (asa). - ravi ägeda st-segmendi elevatsiooniga müokardiinfarkti (stemi), sealhulgas patsiendid, kes käsitatakse konservatiivselt või kes on hiljem läbima perkutaanne koronaarangioplastika (kehtib tugevused 60 mg/0. 6 ml, 80 mg/0. 8 ml ja 100 mg/1 ml). - trombi ennetamise extracorporeal ringlusse ajal hemodialüüsi. ennetamine ja ravi erinevate häired, mis on seotud trombide täiskasvanutele.

Phesgo Euroopa Liit - eesti - EMA (European Medicines Agency)

phesgo

roche registration gmbh - pertuzumab, trastuzumab - rinnanäärmed - antineoplastilised ained - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Enhertu Euroopa Liit - eesti - EMA (European Medicines Agency)

enhertu

daiichi sankyo europe gmbh - trastuzumab deruxtecan - rinnanäärmed - antineoplastilised ained - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Jemperli Euroopa Liit - eesti - EMA (European Medicines Agency)

jemperli

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

VALSARTAN MEDOCHEMIE õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

valsartan medochemie õhukese polümeerikattega tablett

medochemie limited - valsartaan - õhukese polümeerikattega tablett - 160mg 280tk; 160mg 56tk; 160mg 90tk; 160mg 60tk; 160mg 30tk; 160mg 7tk

VALSARTAN MEDOCHEMIE õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

valsartan medochemie õhukese polümeerikattega tablett

medochemie limited - valsartaan - õhukese polümeerikattega tablett - 80mg 28tk; 80mg 14tk; 80mg 60tk; 80mg 7tk; 80mg 280tk; 80mg 30tk; 80mg 98tk; 80mg 90tk

DICLOFENAC MEDOCHEMIE õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

diclofenac medochemie õhukese polümeerikattega tablett

medochemie limited - diklofenak - õhukese polümeerikattega tablett - 12,5mg 10tk; 12,5mg 30tk; 12,5mg 24tk; 12,5mg 40tk; 12,5mg 20tk

FINGOLIMOD MEDOCHEMIE kõvakapsel Eesti - eesti - Ravimiamet

fingolimod medochemie kõvakapsel

medochemie limited - fingolimood - kõvakapsel - 0,5mg 98tk; 0,5mg 28tk; 0,5mg 7tk; 0,5mg 10tk; 0,5mg 30tk

ATORVASTATIN MEDOCHEMIE õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

atorvastatin medochemie õhukese polümeerikattega tablett

medochemie limited - atorvastatiin - õhukese polümeerikattega tablett - 20mg 30tk; 20mg 7tk; 20mg 20tk; 20mg 100tk; 20mg 4tk; 20mg 90tk; 20mg 28tk; 20mg 98tk; 20mg 50tk; 20mg 500tk; 20mg 14tk

ATORVASTATIN MEDOCHEMIE õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

atorvastatin medochemie õhukese polümeerikattega tablett

medochemie limited - atorvastatiin - õhukese polümeerikattega tablett - 10mg 90tk; 10mg 10tk; 10mg 200tk; 10mg 84tk; 10mg 14tk; 10mg 28tk; 10mg 100tk; 10mg 50tk; 10mg 98tk; 10mg 4tk; 10mg 20tk; 10mg 30tk; 10mg 56tk